These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 21756233

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Review of the cardiovascular safety of COXIBs compared to NSAIDS.
    Moodley I.
    Cardiovasc J Afr; 2008; 19(2):102-7. PubMed ID: 18516356
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. How to advise aspirin use in patients who need NSAIDs.
    Sopena F, Lanas A.
    Curr Pharm Des; 2007; 13(22):2248-60. PubMed ID: 17691998
    [Abstract] [Full Text] [Related]

  • 27. Druggable Prostanoid Pathway.
    Mazaleuskaya LL, Ricciotti E.
    Adv Exp Med Biol; 2020; 1274():29-54. PubMed ID: 32894506
    [Abstract] [Full Text] [Related]

  • 28. Prevention of nonsteroidal anti-inflammatory drug-induced ulcer: looking to the future.
    Fiorucci S.
    Gastroenterol Clin North Am; 2009 Jun; 38(2):315-32. PubMed ID: 19446261
    [Abstract] [Full Text] [Related]

  • 29. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC.
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
    Moore RA, Derry S, McQuay HJ.
    BMC Musculoskelet Disord; 2007 Aug 03; 8():73. PubMed ID: 17683540
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Gastrointestinal damage by non-steroidal anti-inflammatory drugs: updated clinical considerations.
    Pellicano R.
    Minerva Gastroenterol Dietol; 2014 Dec 03; 60(4):255-61. PubMed ID: 25384803
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect.
    Chattopadhyay M, Kodela R, Nath N, Dastagirzada YM, Velázquez-Martínez CA, Boring D, Kashfi K.
    Biochem Pharmacol; 2012 Mar 15; 83(6):715-22. PubMed ID: 22222427
    [Abstract] [Full Text] [Related]

  • 37. [TRENDS IN DEVELOPMENT OF GI-SAFE ANTI-INFLAMMATORY DRUGS].
    Sulaieva ON, Wallace JL.
    Klin Med (Mosk); 2017 Mar 15; 95(3):222-7. PubMed ID: 30303341
    [Abstract] [Full Text] [Related]

  • 38. Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: implications for clinical practice.
    Patrício JP, Barbosa JP, Ramos RM, Antunes NF, de Melo PC.
    Clin Drug Investig; 2013 Mar 15; 33(3):167-83. PubMed ID: 23338974
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.